Avadel Pharmaceuticals plc (AVDL)
USD 6.6
(-2.94%)
USD 6.6
(-2.94%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 261.12 Million USD | 96.65% |
| 2022 | 132.78 Million USD | -46.3% |
| 2021 | 247.26 Million USD | -20.66% |
| 2020 | 311.63 Million USD | 105.79% |
| 2019 | 151.43 Million USD | -20.42% |
| 2018 | 190.3 Million USD | -24.52% |
| 2017 | 252.1 Million USD | 2.7% |
| 2016 | 245.48 Million USD | 14.19% |
| 2015 | 214.97 Million USD | 23.4% |
| 2014 | 174.2 Million USD | 49.85% |
| 2013 | 116.25 Million USD | -0.9% |
| 2012 | 117.31 Million USD | 69.03% |
| 2011 | 69.4 Million USD | -6.99% |
| 2010 | 74.61 Million USD | -20.87% |
| 2009 | 94.29 Million USD | 2.65% |
| 2008 | 91.86 Million USD | -9.41% |
| 2007 | 101.4 Million USD | -11.74% |
| 2006 | 114.89 Million USD | -7.61% |
| 2005 | 124.35 Million USD | -14.6% |
| 2004 | 145.6 Million USD | 14.42% |
| 2003 | 127.25 Million USD | 451.45% |
| 2002 | 23.07 Million USD | 27.18% |
| 2001 | 18.14 Million USD | -10.88% |
| 2000 | 20.36 Million USD | 36.46% |
| 1999 | 14.92 Million USD | -41.07% |
| 1998 | 25.31 Million USD | 17.76% |
| 1997 | 21.5 Million USD | -28.09% |
| 1996 | 29.9 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 167.89 Million USD | -35.7% |
| 2024 Q2 | 157.52 Million USD | -6.18% |
| 2023 Q4 | 261.12 Million USD | 28.57% |
| 2023 Q1 | 140.73 Million USD | 5.99% |
| 2023 Q3 | 203.1 Million USD | 1.06% |
| 2023 FY | 261.12 Million USD | 96.65% |
| 2023 Q2 | 200.97 Million USD | 42.8% |
| 2022 Q4 | 132.78 Million USD | -8.9% |
| 2022 FY | 132.78 Million USD | -46.3% |
| 2022 Q1 | 221.12 Million USD | -10.57% |
| 2022 Q2 | 157.93 Million USD | -28.58% |
| 2022 Q3 | 145.75 Million USD | -7.71% |
| 2021 Q3 | 264.08 Million USD | -6.55% |
| 2021 Q4 | 247.26 Million USD | -6.37% |
| 2021 Q1 | 292.94 Million USD | -6.0% |
| 2021 FY | 247.26 Million USD | -20.66% |
| 2021 Q2 | 282.59 Million USD | -3.53% |
| 2020 FY | 311.63 Million USD | 105.79% |
| 2020 Q1 | 207.72 Million USD | 37.17% |
| 2020 Q2 | 341.4 Million USD | 64.35% |
| 2020 Q3 | 327.63 Million USD | -4.03% |
| 2020 Q4 | 311.63 Million USD | -4.88% |
| 2019 Q3 | 155.88 Million USD | -5.93% |
| 2019 Q1 | 173.62 Million USD | -8.76% |
| 2019 FY | 151.43 Million USD | -20.42% |
| 2019 Q4 | 151.43 Million USD | -2.86% |
| 2019 Q2 | 165.7 Million USD | -4.56% |
| 2018 Q2 | 295.23 Million USD | -16.09% |
| 2018 Q1 | 351.86 Million USD | 39.57% |
| 2018 Q4 | 190.3 Million USD | -29.26% |
| 2018 Q3 | 269 Million USD | -8.88% |
| 2018 FY | 190.3 Million USD | -24.52% |
| 2017 Q2 | 259.16 Million USD | 0.18% |
| 2017 Q4 | 252.1 Million USD | -9.13% |
| 2017 FY | 252.1 Million USD | 2.7% |
| 2017 Q1 | 258.68 Million USD | 5.38% |
| 2017 Q3 | 277.42 Million USD | 7.05% |
| 2016 Q3 | 247.98 Million USD | -0.41% |
| 2016 Q4 | 245.48 Million USD | -1.01% |
| 2016 Q2 | 249.01 Million USD | -2.35% |
| 2016 FY | 245.48 Million USD | 14.19% |
| 2016 Q1 | 255.01 Million USD | 18.62% |
| 2015 FY | 214.97 Million USD | 23.4% |
| 2015 Q1 | 186.41 Million USD | 7.0% |
| 2015 Q2 | 186.54 Million USD | 0.07% |
| 2015 Q4 | 214.97 Million USD | 0.0% |
| 2014 Q3 | 164.38 Million USD | -5.87% |
| 2014 Q4 | 174.2 Million USD | 5.97% |
| 2014 Q2 | 174.63 Million USD | -3.91% |
| 2014 FY | 174.2 Million USD | 49.85% |
| 2014 Q1 | 181.74 Million USD | 56.34% |
| 2013 Q1 | 122.73 Million USD | 4.62% |
| 2013 Q2 | 118.4 Million USD | -3.52% |
| 2013 Q3 | 116.51 Million USD | -1.6% |
| 2013 Q4 | 116.25 Million USD | -0.22% |
| 2013 FY | 116.25 Million USD | -0.9% |
| 2012 Q4 | 117.31 Million USD | 0.0% |
| 2012 Q2 | 133.71 Million USD | -2.69% |
| 2012 FY | 117.31 Million USD | 69.03% |
| 2012 Q1 | 137.41 Million USD | 97.99% |
| 2011 FY | 69.4 Million USD | -6.99% |
| 2011 Q1 | 69.98 Million USD | -6.21% |
| 2011 Q2 | 76.11 Million USD | 8.77% |
| 2011 Q3 | 72.69 Million USD | -4.49% |
| 2011 Q4 | 69.4 Million USD | -4.53% |
| 2010 Q1 | 81.25 Million USD | -13.83% |
| 2010 FY | 74.61 Million USD | -20.87% |
| 2010 Q4 | 74.61 Million USD | -3.58% |
| 2010 Q3 | 77.38 Million USD | 9.8% |
| 2010 Q2 | 70.48 Million USD | -13.26% |
| 2009 Q3 | 97.92 Million USD | 5.01% |
| 2009 Q4 | 94.29 Million USD | -3.7% |
| 2009 FY | 94.29 Million USD | 2.65% |
| 2009 Q1 | 91.08 Million USD | -0.85% |
| 2009 Q2 | 93.25 Million USD | 2.39% |
| 2008 Q3 | 88.76 Million USD | -12.19% |
| 2008 FY | 91.86 Million USD | -9.41% |
| 2008 Q1 | 105.19 Million USD | 3.74% |
| 2008 Q2 | 101.09 Million USD | -3.9% |
| 2008 Q4 | 91.86 Million USD | 3.49% |
| 2007 FY | 101.4 Million USD | -11.74% |
| 2007 Q4 | 101.4 Million USD | -2.42% |
| 2007 Q3 | 103.91 Million USD | -2.37% |
| 2007 Q2 | 106.43 Million USD | -1.87% |
| 2007 Q1 | 108.46 Million USD | -5.6% |
| 2006 Q3 | 111.26 Million USD | -2.1% |
| 2006 Q4 | 114.89 Million USD | 3.26% |
| 2006 Q2 | 113.64 Million USD | -2.26% |
| 2006 Q1 | 116.27 Million USD | -6.49% |
| 2006 FY | 114.89 Million USD | -7.61% |
| 2005 Q2 | 142.58 Million USD | -2.31% |
| 2005 FY | 124.35 Million USD | -14.6% |
| 2005 Q4 | 124.35 Million USD | -2.83% |
| 2005 Q3 | 127.97 Million USD | -10.25% |
| 2005 Q1 | 145.95 Million USD | 0.23% |
| 2004 Q4 | 145.6 Million USD | 17.21% |
| 2004 Q3 | 124.23 Million USD | 0.0% |
| 2004 FY | 145.6 Million USD | 14.42% |
| 2004 Q1 | 127.59 Million USD | 0.27% |
| 2004 Q2 | 124.23 Million USD | -2.63% |
| 2003 FY | 127.25 Million USD | 451.45% |
| 2003 Q4 | 127.25 Million USD | 285.36% |
| 2003 Q2 | 23.85 Million USD | 1.17% |
| 2003 Q1 | 23.58 Million USD | 2.18% |
| 2003 Q3 | 33.02 Million USD | 38.42% |
| 2002 Q3 | 21.67 Million USD | 0.0% |
| 2002 FY | 23.07 Million USD | 27.18% |
| 2002 Q4 | 23.07 Million USD | 6.47% |
| 2001 Q4 | 18.14 Million USD | 0.0% |
| 2001 FY | 18.14 Million USD | -10.88% |
| 2000 Q4 | 20.36 Million USD | 0.0% |
| 2000 FY | 20.36 Million USD | 36.46% |
| 1999 Q4 | 14.92 Million USD | 0.0% |
| 1999 FY | 14.92 Million USD | -41.07% |
| 1998 Q4 | 25.31 Million USD | 0.0% |
| 1998 Q1 | 18.9 Million USD | -12.09% |
| 1998 FY | 25.31 Million USD | 17.76% |
| 1997 FY | 21.5 Million USD | -28.09% |
| 1997 Q4 | 21.5 Million USD | 0.0% |
| 1996 Q4 | 29.9 Million USD | 0.0% |
| 1996 FY | 29.9 Million USD | 0.0% |
| 1996 Q1 | 4.7 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Cosmos Health Inc. | 66.29 Million USD | -293.882% |
| Safety Shot Inc | 12.7 Million USD | -1954.625% |
| Bright Green Corporation | 17.4 Million USD | -1400.461% |
| Embecta Corp. | 1.21 Billion USD | 78.498% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 71.128% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | -354.781% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 77.16% |
| Dynavax Technologies Corporation | 997.09 Million USD | 73.811% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -26.886% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 64.146% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 83.414% |
| PainReform Ltd. | 9.93 Million USD | -2529.668% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -854.863% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -854.863% |
| SCYNEXIS, Inc. | 128.41 Million USD | -103.35% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -1029.093% |
| Journey Medical Corporation | 76.84 Million USD | -239.791% |
| Alpha Teknova, Inc. | 128.58 Million USD | -103.073% |
| Procaps Group, S.A. | 460.18 Million USD | 43.257% |
| Theratechnologies Inc. | 77.76 Million USD | -235.771% |
| Harrow Health, Inc. | 311.75 Million USD | 16.24% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -1653.347% |
| Biofrontera Inc. | 27.93 Million USD | -834.863% |
| DURECT Corporation | 45.18 Million USD | -477.853% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 81.467% |
| Cronos Group Inc. | 1.13 Billion USD | 76.978% |
| OptiNose, Inc. | 107.72 Million USD | -142.392% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 44.568% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -366.721% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -1033.008% |
| Organogenesis Holdings Inc. | 460.02 Million USD | 43.237% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -2090.989% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | -219.318% |
| Radius Health, Inc. | 1.71 Billion USD | 84.782% |
| Universe Pharmaceuticals INC | 53.28 Million USD | -390.037% |
| ProPhase Labs, Inc. | 91.92 Million USD | -184.058% |
| Phibro Animal Health Corporation | 982.18 Million USD | 73.414% |
| Procaps Group S.A. | 460.18 Million USD | 43.257% |
| Alvotech | 950.09 Million USD | 72.516% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -502.937% |
| Viatris Inc. | 47.68 Billion USD | 99.452% |
| Rockwell Medical, Inc. | 52.17 Million USD | -400.5% |
| Aytu BioPharma, Inc. | 118.09 Million USD | -121.115% |
| SIGA Technologies, Inc. | 254.83 Million USD | -2.468% |
| Tilray Brands, Inc. | 4.33 Billion USD | 93.977% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | 4.595% |
| Shineco, Inc. | 84.17 Million USD | -210.202% |
| PetIQ, Inc. | 868.22 Million USD | 69.924% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -2994.566% |
| Incannex Healthcare Limited | 17.04 Million USD | -1431.8% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 91.969% |
| Alimera Sciences, Inc. | 153.52 Million USD | -70.088% |
| Silver Spike Investment Corp. | 88.57 Million USD | -194.804% |
| Assertio Holdings, Inc. | 286.41 Million USD | 8.831% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -4287.392% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -672.658% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -735.79% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -1871.129% |
| Hempacco Co., Inc. | 18.04 Million USD | -1347.236% |
| Talphera, Inc. | 20.39 Million USD | -1180.343% |
| Alvotech | 950.09 Million USD | 72.516% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | 35.709% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 84.185% |
| Currenc Group, Inc. | 141.49 Million USD | -84.554% |
| Kamada Ltd. | 351.96 Million USD | 25.81% |
| Indivior PLC | 1.95 Billion USD | 86.617% |
| Evoke Pharma, Inc. | 7.06 Million USD | -3594.197% |
| Flora Growth Corp. | 23.62 Million USD | -1005.248% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -1871.129% |
| Evolus, Inc. | 188.99 Million USD | -38.163% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 79.596% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 82.74% |
| Akanda Corp. | 8.83 Million USD | -2853.916% |